An unwanted side effect: Giant hepatocellular carcinoma development after ledipasvir/sofosbuvir therapy in a chronic hepatitis C virus-induced cirrhotic patient

Year 2018, Volume: 3 Issue: 1-2, 6 - 8, 04.04.2019

Tolga Şahin , Ayfer Serin

Abstract

Hepatocellular carcinoma (HCC) is the fifth common cancer and the second cause of cancer-related death worldwide. Hepatitis C virus (HCV) is a common cause of chronic hepatitis, liver cirrhosis, and HCC. Recently, some new drugs have been developed named direct-acting antivirals (DAAs) for chronic HCV treatment. Direct-acting antivirals provide sustained viral response and total cure in over 80% of chronic hepatitis C patients. In this article, we present a patient with HCV genotype 1b-induced cirrhosis with giant HCC development after ledipasvir/sofosbuvir combination therapy. Although chronic hepatitis C infection can be cured with the combination of new generation DAAs, HCC pathogenesis and development risk in cirrhotic cases are still unclear. Thus, cirrhotic patients treated with DAAs should be followed-up at close intervals after treatment.

Keywords

Hepatitis C virus, hepatocellular carcinoma, ledipasvir, sofosbuvir

References

• 1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161-76. 2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27. 3. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015;385:1124-35. 4. Soliman MS, Soliman YY, Ahmad Q, Yarlagadda R. An unfortunate failure: multifocal hepatocellular carcinoma in a non-cirrhotic patient with chronic hepatitis C treated with ledipasvir/sofosbuvir. J Community Hosp Intern Med Perspect 2018;8:167-9.